<DOC>
	<DOCNO>NCT02519049</DOCNO>
	<brief_summary>Prospective exploratory study specifically investigate role 11C-Methionine PET/CT imaging patient affect Malignant Pleural Mesothelioma ( MPM ) candidate pleurodesis .</brief_summary>
	<brief_title>11C-Methionine PET/CT Imaging Patients Affected Malignant Pleural Mesothelioma ( MPM )</brief_title>
	<detailed_description>This single-center , open-label study , last 36 month include estimated period 24 month enrollment max 12 month follow-up . All patient affect MPM refer Institution eligible therapeutic pleurodesis subsequent platinum- pemetrexed-based chemotherapy enrol . In case patient investigated 11C-Methionine PET/CT 18F-FDG PET/CT talc pleurodesis , one week end three cycle chemotherapy . A minimum number 20 patient consider analysis .</detailed_description>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<criteria>patient histological diagnosis MPM eligible pleurodesis schedule undergo platinum pemetrexedbased chemotherapy . obtain informed consent patient age &lt; 18 year pregnancy breastfeeding ; patient affect malignancy within last 3 year ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Mesothelioma</keyword>
	<keyword>11C-methionine PET</keyword>
	<keyword>talc pleurodesis</keyword>
</DOC>